Overview

* ENDRA Q3 2025 cash burn decreased 30% to $1.2 mln due to cost optimization

* Company completed $4.9 mln private placement, regaining Nasdaq compliance

* Operating expenses for Q3 2025 were $1.4 mln, down from $1.5 mln in 2024

Outlook

* Strategic initiative launched to enhance financial sustainability

Result Drivers

* COST OPTIMIZATION - Q3 cash burn decreased 30% due to streamlined staffing and reduced overhead

* PIPE FINANCING - $4.9 mln private placement completed, aiding Nasdaq compliance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $1.40

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for ENDRA Life Sciences Inc ( NDRA ) is $38.00, about 82.4% above its November 14 closing price of $6.70

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)